Sudeep Pharma Ltd (SUDEEPPHRM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544619 | NSE: SUDEEPPHRM | Pharmaceuticals & Drugs | Small Cap

Sudeep Pharma Share Price

668 -2.25 -0.34%
as on 05-Dec'25 10:39

Sudeep Pharma Ltd (SUDEEPPHRM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544619 | NSE: SUDEEPPHRM | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Sudeep Pharma

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Sudeep Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
79.07
Market Cap:
7,570.4 Cr.
52-wk low:
658.2
52-wk high:
795.8

Is Sudeep Pharma Ltd an attractive stock to invest in?

1. Is Sudeep Pharma Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sudeep Pharma Ltd is a good quality company.

2. Is Sudeep Pharma Ltd undervalued or overvalued?

The key valuation ratios of Sudeep Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Sudeep Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sudeep Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Sudeep Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sudeep Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 22.1%29.1%26%28.9%29.8%37%37.1%34.6%38.9%28.7%-
Value Creation
Index
0.61.20.91.11.21.71.81.61.91.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 44.55058.789.1123218345404344357357
Sales YoY Gr.-12.5%17.4%51.7%38.1%77.1%58.3%17.1%-14.9%3.8%-
Adj EPS 0.50.711.11.83.456.39.89.58.5
YoY Gr.-58.7%30.1%17.9%60.7%90%46.2%25%56.8%-3.4%-
BVPS (₹) 3.54.35.36.58.311.917.324.434.54446.4
Adj Net
Profit
4.57.19.210.917.433.248.660.695.192.196
Cash Flow from Ops. 10.43.713.412.99.935.8-5.342.359.159.2-
Debt/CF from Ops. 0.21.10.30.620.9-13.61.712-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 26%23.7%1.1%3.8%
Adj EPS 39.9%39.4%23.7%-3.4%
BVPS32.4%39.5%36.4%27.7%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
16.418.719.81924.233.734.229.933.324.118.8
Op. Profit
Mgn %
1723.921.619.720.62119.821.938.837.3NAN
Net Profit
Mgn %
10.114.215.712.214.215.214.11527.725.826.8
Debt to
Equity
0.10.10.10.10.30.30.40.30.20.3-
Working Cap
Days
1341201311131291201432052923110
Cash Conv.
Cycle
474659576967911111231550

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 23.73%

Return on Equity has declined versus last 3 years average to 18.80%

Sales growth has been subdued in last 3 years 1.13%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Sudeep Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 8.5 12.3
TTM Sales (₹ Cr.) 357 502
BVPS (₹.) 46.4 52
Reserves (₹ Cr.) 513 576
P/BV 14.44 12.89
PE 79.07 54.58
From the Market
52 Week Low / High (₹) 658.20 / 795.80
All Time Low / High (₹) 707.80 / 795.80
Market Cap (₹ Cr.) 7,570
Equity (₹ Cr.) 11.3
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Sudeep Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Sudeep Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Sudeep Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales44505989123218345404344357
Operating Expenses 3738467298172277316211224
Manufacturing Costs86710101319212731
Material Costs192125324583135175126119
Employee Cost 446791114142026
Other Costs 6792334641101073748
Operating Profit 712131825466888133133
Operating Profit Margin (%) 16.9%23.8%21.5%19.7%20.6%21.0%19.8%21.8%38.7%37.2%
Other Income 11233481188
Interest 1001112446
Depreciation 1122344556
Exceptional Items 0000000000
Profit Before Tax 712131825457091132129
Tax 243671018243434
Profit After Tax 57912183552679896
PAT Margin (%) 10.7%14.9%16.1%13.2%14.7%16.1%15.2%16.6%28.5%26.8%
Adjusted EPS (₹)0.50.81.01.21.93.65.46.910.19.9
Dividend Payout Ratio (%)16%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 3442516381116168237335430
Share Capital 11111111112
Reserves 3340506180115167235333418
Minority Interest0000000000
Debt24471731737051111
Long Term Debt00118141711536
Short Term Debt242691755594675
Trade Payables346691724393436
Others Liabilities 34516245068703027
Total Liabilities 42546693131214333416451604

Fixed Assets

Gross Block30323963728313986106120
Accumulated Depreciation567912161941015
Net Fixed Assets 2526325460681208196105
CWIP 01918234264388
Investments 141062415192932
Inventories494891526524565
Trade Receivables5713183058123126141162
Cash Equivalents 113448156945
Others Assets 664813173010587107
Total Assets 42546693131214333416451604

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 10413131036-5425959
PBT 712131825457091132129
Adjustment 21234451389
Changes in Working Capital 4-62-4-13-3-64-39-45-50
Tax Paid -2-3-3-4-6-11-17-22-36-30
Cash Flow From Investing Activity -7-6-12-15-22-45-28-41-41-92
Capex -6-2-8-24-9-12-56-38-32-61
Net Investments -1-331-600-33-15
Others 0-0-88-7-33280-12-16
Cash Flow From Financing Activity -32-03121340-10-1654
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -1021101442-6-832
Interest Paid -1-0-0-1-1-1-2-4-3-4
Dividend Paid -1000000000
Others -12-234-0-0-0-527
Net Cash Flow 1012-047-9222

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)17.3619.5820.320.625.0835.5436.8133.1634.3225.12
ROCE (%)22.0829.126.0328.9329.7537.0237.1434.5638.928.72
Asset Turnover Ratio1.161.141.011.131.11.261.261.080.790.68
PAT to CFO Conversion(x)20.571.441.080.561.03-0.10.630.60.61
Working Capital Days
Receivable Days51396063727496113142155
Inventory Days40413926272122365256
Payable Days8158717061565566106108

Sudeep Pharma Ltd Stock News

Sudeep Pharma Ltd FAQs

The current trading price of Sudeep Pharma on 05-Dec-2025 10:39 is ₹668.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Sudeep Pharma stood at ₹7,570.4.
The latest P/E ratio of Sudeep Pharma as of 04-Dec-2025 is 79.07.
The latest P/B ratio of Sudeep Pharma as of 04-Dec-2025 is 14.44.
The 52-week high of Sudeep Pharma is ₹795.8 and the 52-week low is ₹658.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sudeep Pharma is ₹356.7 ( Cr.) .

About Sudeep Pharma Ltd

Sudeep Pharma was incorporated as ‘Sudeep Pharma Private Limited’ as a private limited company on December 21, 1989 in Gujarat at Ahmedabad. Thereafter, the company was converted into a public limited company and the name of the company was accordingly changed to ‘Sudeep Pharma Limited’. The company was subsequently converted back to a private limited company and the name of the company was accordingly changed from ‘Sudeep Pharma Limited’ to ‘Sudeep Pharma Private Limited’. Further, pursuant to the special resolution passed by the shareholders dated August 17, 2024 and the company was converted into a public limited company and consequently, the name of the company was changed to ‘Sudeep Pharma Limited’.

The company is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries. It is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors. It is one of the largest exporters of mineral ingredients for pharmaceutical, food and nutrition industries from India to global markets. It is one of few companies with certification of suitability issued by the Council of Europe (CEP) and written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient (API) in the European Union. 

It leverages its inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in its operations. It has established a presence in both, domestic and international markets. 

Business area of the company 

The company along with its subsidiary companies is engaged in business of manufacturing of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem by providing excipients and specialty ingredients. It develops solutions that enhance vitality, functionality, and efficiency in consumer products.

Business verticals of the company

  • Pharmaceutical, Food and Nutrition Business - The company provides mineral-based ingredients for a wide range of applications in the pharmaceutical, food, and nutrition industries. Its offering includes essential mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, simethicone and copper.
  • Specialty Ingredients Business - The company develops and manufactures innovative specialty ingredients, which serve various sectors such as food, nutrition, pharmaceuticals, and health supplement. Its offering includes Micro-nutrient Premixes, Liposomal Ingredients, Encapsulated Ingredients, Spray Dried Ingredients and Granulated Ingredients.
  • Triturates - The company’s Tritunova line of triturated nutrients provides a uniform micronutrient blend on a carrier substrate, ensuring consistent distribution of active nutrients when incorporated into final products.

Awards, accreditations and recognition 

  • 2008: ‘Certificate of Appreciation for the years 2008-09 in the Exports category of Small Scale Industries’ awarded by Pharmexcil to the company.
  • 2016: ‘Appreciation for contribution as a Business Partner’ awarded by Abbott to the company.
  • 2021: ‘Certificate of Membership’ awarded by PRM Industries Association to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
  • 2021: ‘Appreciation for contribution during COVID’ awarded by Abbott to the company.
  • 2023: ‘Certificate of Appreciation’ awarded by the Federation of Telangana Chambers of Commerce and Industry (FTCCI), Hyderabad to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
  • 2023: ‘Excellence Award for Excellence in Innovative Ingredients Manufacturing’ awarded by ASSOCHAM to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
  • 2023: ‘Suppliers Summit 2023 Award’ awarded by Herbalife to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
  • 2023: ‘Global Indian MSME of the Year in Manufacturing’ awarded by The Economic Times to the company at ‘The Economic Times MSME Awards 2023’.
  • 2023: ‘Customer Centric Business Partner’ awarded by Abbott to the company.
  • 2024 ‘FRK Manufacturing Excellence Award’ awarded by Millers for Nutrition to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.

History and milestones

  • 1989: Incorporation of the company.
  • 2017: The company obtained USFDA certification for mineral based ingredients.
  • 2020: Incorporation of the company’s subsidiary, Sudeep Pharma USA Inc.
  • 2021: Incorporation of the company’s subsidiary, Sudeep Nutrition Private Limited.
  • 2022: The company obtained written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient.
  • 2023: Incorporation of the company’s subsidiary, Sudeep Pharma B.V.
  • 2024: Incorporation of the company’s subsidiary, Sudeep Advanced Materials Private Limited.
  • 2024: The company’s subsidiary, Sudeep Nutrition Private Limited, introduced liposomal encapsulation of nutrients for enhanced absorption.
  • 2025: Acquisition of the company’s step-down subsidiary, Nutrition Supplies and Services (Ireland) Limited.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×